Results 261 to 270 of about 366,723 (337)
Objective The objective of this study was to show the capacity of structural brain magnetic resonance imaging (MRI) measures to serve as monitoring biomarkers for Fragile X‐Associated Tremor/Ataxia Syndrome (FXTAS). Methods From 2 longitudinal studies of male FMR1 premutation carriers, 2 brain MRI scans were selected from each participant, collected ...
David Hessl+6 more
wiley +1 more source
Reactive astrocyte-derived neurotoxicity is mitigated by vitronectin in traumatic brain injury mouse model. [PDF]
Yamashita M+6 more
europepmc +1 more source
Autosomal Recessive Cerebellar Ataxias: Translating Genes to Therapies
Autosomal recessive cerebellar ataxias are disabling neurodegenerative genetic conditions affecting balance and coordination. Advancements in genomic testing have improved diagnosis, leading to a new focus on the development of targeted precision therapeutics addressing cellular, biochemical, and genetic disease mechanisms with a resulting emphasis on ...
Brent L. Fogel+10 more
wiley +1 more source
Mapping Disorders with Neurological Features Through Mitochondrial Impairment Pathways: Insights from Genetic Evidence. [PDF]
Makridou A+6 more
europepmc +1 more source
Synthesis of Literature: Neurodegeneration in Moderate‐Severe TBI. Objective Although moderate‐to‐severe traumatic brain injury (msTBI) was once considered a static neural event following resolution of acute injuries, numerous studies now demonstrate progressive losses to volume and white matter integrity in the months and years postinjury, leading to ...
Bhanu Sharma+4 more
wiley +1 more source
Memantine Exacerbates Trimethyltin-Induced Neurodegeneration and Delays Cognitive Impairment Recovery. [PDF]
Onaka Y+4 more
europepmc +1 more source
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks
Objective The objective of this study was to evaluate the timing of change of Alzheimer's disease (AD) plasma biomarkers (Aβ42/Aβ40, p‐tau217, p‐tau181, GFAP, and NfL) from six different assay platforms, alongside established AD biomarkers, using amyloid and tau positron emission tomography (PET)‐based AD progression timelines.
Marta Milà‐Alomà+27 more
wiley +1 more source
Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms. [PDF]
Coclitu CI+2 more
europepmc +1 more source